New therapy for pancreatic cancer based on extracellular vesicles
Tài liệu tham khảo
Miller, 2016, Cancer treatment and survivorship statistics, 2016, CA Cancer J. Clin., 66, 271, 10.3322/caac.21349
Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 209, 10.3322/caac.21660
Adamska, 2017, Pancreatic ductal adenocarcinoma: current and evolving therapies, Int. J. Mol. Sci., 18
Abbruzzese, 2008, Adjuvant therapy for surgically resected pancreatic adenocarcinoma, JAMA, 299, 1066, 10.1001/jama.299.9.1066
Fang, 2015, Temozolomide nanoparticles for targeted glioblastoma therapy, ACS Appl. Mater. Interfaces, 7, 6682, 10.1021/am5092165
Gronchi, 2021, Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 32, 1348, 10.1016/j.annonc.2021.07.006
Casali, 2018, Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 29, iv79, 10.1093/annonc/mdy310
Nabors, 2020, Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology, J. Natl. Compr. Canc. Netw., 18, 1537, 10.6004/jnccn.2020.0052
von Mehren, 2020, NCCN guidelines insights: soft tissue sarcoma, Version 1.2021, J. Natl. Compr. Cancer Netw., 18, 1605
Swetter, 2021, NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021, J. Natl. Compr. Cancer Netw., 19, 364, 10.6004/jnccn.2021.0018
Pavel, 2020, Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 31, 844, 10.1016/j.annonc.2020.03.304
Stupp, 2014, High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 25, iii93, 10.1093/annonc/mdu050
Moore, 1998, A phase II study of temozolomide in advanced untreated pancreatic cancer, Invest. N. Drugs, 16, 77, 10.1023/A:1006043332368
Ostermann, 2004, Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients, Clin. Cancer Res., 10, 3728, 10.1158/1078-0432.CCR-03-0807
Sengupta, 2012, Impact of temozolomide on immune response during malignant glioma chemotherapy, Clin. Dev. Immunol., 2012, 10.1155/2012/831090
Chamberlain, 2014, Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas, Expert Rev. Neurother., 10, 1537, 10.1586/ern.10.32
Trinh, 2009, The safety of temozolomide in the treatment of malignancies, Expert Opin. Drug Saf., 8, 493, 10.1517/14740330902918281
Chan-Penebre, 2015, A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models, Nat. Chem. Biol., 11, 432, 10.1038/nchembio.1810
Stopa, 2015, The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond, Cell. Mol. life Sci., 72, 2059, 10.1007/s00018-015-1847-9
Wang, 2018, Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery, J. Med. Chem., 61, 9429, 10.1021/acs.jmedchem.8b00598
Vinet, 2019, Protein arginine methyltransferase 5: a novel therapeutic target for triple‐negative breast cancers, Cancer Med, 8, 2428, 10.1002/cam4.2114
Singh, 2016, Exosome-mediated transfer of Αvβ3 integrin from tumorigenic to nontumorigenic cells promotes a migratory phenotype, Mol. Cancer Res., 14, 1136, 10.1158/1541-7786.MCR-16-0058
Colombo, 2014, Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles, Annu. Rev. Cell Dev. Biol., 30, 255, 10.1146/annurev-cellbio-101512-122326
Wang, 2019, Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer, Mol. Carcinog., 58, 674, 10.1002/mc.22960
Araujo-Abad, 2022, Biomedical application of small extracellular vesicles in cancer treatment, Adv. Drug Deliv. Rev., 182, 10.1016/j.addr.2022.114117
Qiao, 2020, Tumor cell-derived exosomes home to their cells of origin and can be used as trojan horses to deliver cancer drugs, Theranostics, 10, 3474, 10.7150/thno.39434
Batrakova, 2015, Using exosomes, naturally-equipped nanocarriers, for drug delivery, J. Control. Release, 219, 396, 10.1016/j.jconrel.2015.07.030
Tian, 2014, A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials, 35, 2383, 10.1016/j.biomaterials.2013.11.083
Nam, 2018, Drug delivery nanosystems for the localized treatment of glioblastoma multiforme, Mater. (Basel), 11
Bazeed, A.Y.; Day, C.M.; Garg, S. Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies. Cancers 2022, Vol. 14, Page 4257 2022, 14, 4257, doi:10.3390/CANCERS14174257.
Fuentes-Baile, 2020, CLyta-DAAO, free and immobilized in magnetic nanoparticles, induces cell death in human cancer cells, Biomolecules, 10, 222, 10.3390/biom10020222
Ventero, 2019, Radiotherapy resistance acquisition in glioblastoma. Role of SOCS1 and SOCS3, PLoS One, 14
Neira, 2022, Biochemical and biophysical characterization of PADI4 supports its involvement in cancer, Arch. Biochem. Biophys., 717, 10.1016/j.abb.2022.109125
Dexter, 1982, Establishment and characterization of two human pancreatic cancer cell lines tumorigenic in athymic mice, Cancer Res., 42, 2705
Fuentes-Baile, 2020, Differential effects of IGF-1R small molecule tyrosine kinase inhibitors BMS-754807 and OSI-906 on human cancer cell lines, Cancers (Basel), 12, 1, 10.3390/cancers12123717
Fuentes-Baile, 2021, Clyta-daao chimeric enzyme bound to magnetic nanoparticles. A new therapeutical approach for cancer patients?, Int. J. Mol. Sci., 22, 1, 10.3390/ijms22031477
Fuentes‐baile, 2020, Cell death mechanisms induced by CLytA‐DAAO chimeric enzyme in human tumor cell lines, Int. J. Mol. Sci., 21, 1, 10.3390/ijms21228522
Araujo-Abad, S.; Manresa-Manresa, A.; Rodríguez-Cañas, E.; Fuentes-Baile, M.; García-Morales, P.; Mallavia, R.; Saceda, M.; De, C.; Romero, J. Glioblastoma-Derived Small Extracellular Vesicles: Nanoparticles for Glioma Treatment. Int. J. Mol. Sci. 2023, Vol. 24, Page 5910 2023, 24, 5910, doi:10.3390/IJMS24065910.
Zhang, 2019, Exosomes: biogenesis, biologic function and clinical potential, Cell Biosci., 9, 1, 10.1186/s13578-019-0282-2
Sokolova, 2011, Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy, Colloids Surf. B Biointerfaces, 87, 146, 10.1016/j.colsurfb.2011.05.013
Sarantis, 2020, Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy, World J. Gastrointest. Oncol., 12, 173, 10.4251/wjgo.v12.i2.173
Principe, 2021, The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy, Front. Oncol., 11, 2773, 10.3389/fonc.2021.688377
Casper, 1994, Phase II trial of gemcitabine (2,2’-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas, Invest. N. Drugs, 12, 29, 10.1007/BF00873232
Carmichael, 1996, Phase II study of gemcitabine in patients with advanced pancreatic cancer, Br. J. Cancer, 73, 101, 10.1038/bjc.1996.18
Moore, 1996, Activity of gemcitabine in patients with advanced pancreatic carcinoma a review BACKGROUND. In early phase I1 trials in advanced pancreatic cancer, Gemcitabine. Cancer, 78, 633, 10.1002/(SICI)1097-0142(19960801)78:3+<633::AID-CNCR8>3.0.CO;2-B
Robertson, 2016, Essential medicines for cancer: WHO recommendations and national priorities, Bull. World Health Organ, 94, 742, 10.2471/BLT.15.163998
Wei, 2020, Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells, Proc. Natl. Acad. Sci. U. S. A., 117, 28068, 10.1073/pnas.2009899117
Braun, 2017, Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma, Cancer Cell, 32, 411, 10.1016/j.ccell.2017.08.018
Liu, 2021, EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma, Exp. Eye Res., 202, 10.1016/j.exer.2020.108286
Xi, 2021, Drug loading techniques for exosome-based drug delivery systems, Pharmazie, 76, 61
Wu, 2021, Preservation of small extracellular vesicles for functional analysis and therapeutic applications: a comparative evaluation of storage conditions, Drug Deliv., 28, 162, 10.1080/10717544.2020.1869866
Siegel, 2016, Cancer Statistics, 2016, CA Cancer J. Clin., 66, 7, 10.3322/caac.21332
Li, 2016, Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy, Oncotarget, 7, 24585, 10.18632/oncotarget.8358
Howlader, N.; Noone, A.; Krapcho, M. SEER Cancer Statistics Review (CSR) 1975–2017. National Cancer Institute Available online: https://seer.cancer.gov/archive/csr/1975_2017/ (accessed on 30 September 2022).
Conroy, 2018, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N. Engl. J. Med., 379, 2395, 10.1056/NEJMoa1809775
Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N. Engl. J. Med., 350, 1200, 10.1056/NEJMoa032295
Laviano, 2005, Therapy insight: cancer anorexia-cachexia syndrome--when all you can eat is yourself, Nat. Clin. Pract. Oncol., 2, 158, 10.1038/ncponc0112
Grossberg, 2020, Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma, Ca. Cancer J. Clin., 70, 375, 10.3322/caac.21626
Babic, 2019, Post diagnosis loss of skeletal muscle, but not adipose tissue, is associated with shorter survival of patients with advanced pancreatic cancer, Cancer Epidemiol. Biomark. Prev., 28, 2062, 10.1158/1055-9965.EPI-19-0370
Kays, 2018, Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer, J. Cachex. Sarcopenia Muscle, 9, 673, 10.1002/jcsm.12307
Bachmann, 2008, Cachexia worsens prognosis in patients with resectable pancreatic cancer, J. Gastrointest. Surg., 12, 1193, 10.1007/s11605-008-0505-z
Hendifar, 2016, Influence of body mass index and albumin on perioperative morbidity and clinical outcomes in resected pancreatic adenocarcinoma, PLoS One, 11, 10.1371/journal.pone.0152172
Görgens, 2022, Identification of storage conditions stabilizing extracellular vesicles preparations, J. Extracell. Vesicles, 11, 10.1002/jev2.12238
Sivanantham, 2022, Impact of storage conditions on EV integrity/surface markers and cargos, Life, 12, 697, 10.3390/life12050697
Zhang, 2020, Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications, Int. J. Nanomed., 15, 6917, 10.2147/IJN.S264498